Enter a keyword or phrase to search all pages in this section:

Advanced search


Looking for a previously published document in this section?

Advertising complaint - Yasmin (drospirenone/ ethinylestradiol) - Advert published in healthcare professional journals - January 2009

A healthcare professional complained to the MHRA about an advertisement for Yasmin produced by Bayer Healthcare, which was published in January 2009 in a number of healthcare professional journals including the Journal of Family Planning and Reproductive Healthcare. The complainant was concerned that the advertisement was misleading because it contained the claim, “Drospirenone has a positive effect on… fluid retention” which was not supported by adequate evidence.

The MHRA upheld the complaint and determined the advertisement to be in breach of regulations 3A(2) and 3A(3) of the Advertising Regulations. Bayer withdrew the advertisement and published a corrective statement.

Date case raised: 19 January 2009
Date action agreed: 21 April 2009
Date of publication: 21 August 2009 

Page last modified: 21 August 2009